CA3049501C - Compositions et procedes pour la depletion des cellules cd137+ - Google Patents

Compositions et procedes pour la depletion des cellules cd137+

Info

Publication number
CA3049501C
CA3049501C CA3049501A CA3049501A CA3049501C CA 3049501 C CA3049501 C CA 3049501C CA 3049501 A CA3049501 A CA 3049501A CA 3049501 A CA3049501 A CA 3049501A CA 3049501 C CA3049501 C CA 3049501C
Authority
CA
Canada
Prior art keywords
antibody
adc
cells
amatoxin
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3049501A
Other languages
English (en)
Other versions
CA3049501A1 (fr
Inventor
Adam HARTIGAN
Anthony Boitano
Michael Cooke
Megan D. Hoban
Rahul Palchaudhuri
Original Assignee
Heidelberg Pharma Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Research GmbH filed Critical Heidelberg Pharma Research GmbH
Priority claimed from PCT/IB2018/050365 external-priority patent/WO2018134787A2/fr
Publication of CA3049501A1 publication Critical patent/CA3049501A1/fr
Application granted granted Critical
Publication of CA3049501C publication Critical patent/CA3049501C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des procédés de prévention et de traitement d'une maladie du greffon contre l'hôte et de maladies auto-immunes, telles que celles provenant d'une thérapie de transplantation, par déplétion sélective de cellules hématopoïétiques par l'utilisation de conjugués anticorps-médicament et de conjugués ligand-médicament qui se lient spécifiquement à CD137. Les compositions et les procédés de l'invention peuvent être utilisés pour traiter une variété de pathologies, y compris des troubles des cellules souches et d'autres états sanguins.
CA3049501A 2017-01-20 2018-01-19 Compositions et procedes pour la depletion des cellules cd137+ Active CA3049501C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762448741P 2017-01-20 2017-01-20
US62/448,741 2017-01-20
US201762595977P 2017-12-07 2017-12-07
US62/595,977 2017-12-07
PCT/IB2018/050365 WO2018134787A2 (fr) 2017-01-20 2018-01-19 Compositions et procédés pour la déplétion des cellules cd137+

Publications (2)

Publication Number Publication Date
CA3049501A1 CA3049501A1 (fr) 2018-07-26
CA3049501C true CA3049501C (fr) 2026-01-20

Family

ID=

Similar Documents

Publication Publication Date Title
US20240207428A1 (en) Compositions and methods for the depletion of cells
US10434185B2 (en) Compositions and methods for the depletion of CD137+ cells
AU2018200503C1 (en) Compositions and methods for the depletion of cd117+ cells
US20190144563A1 (en) T cell receptor-like antibodies specific for a wti peptide presented by hla-a2
US20210101990A1 (en) Compositions and methods for the depletion of cd134+ cells